NVO News

Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers' hands

PharmaZee GLP-1 Prescription Information Updated as Novo Nordisk Raises Compounding Concerns and Consumer Interest in Telehealth Semaglutide Access Grows in 2026

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk files annual report with the SEC

Team Novo Nordisk return to Milan-Sanremo in 2026

Novo Nordisk initiates 2026 share repurchase programme

Novo Nordisk has published its annual report for 2025

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

Smart Insulin Pens Market Driven by 11.34% CAGR and Rising Diabetes Prevalence